An Open Label, Multicenter, Phase Ib/Il Study to Evaluate the Safety, Tolerability, and Efficacy of SHR A2102 in Combination With Other Anti-cancer Agents in Patients With Advanced Urothelial Carcinoma
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.
• Competent to comprehend, sign, and date an informed consent form.
• Male or female subjects must be age 18 or older.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Subjects must have histologically documented, unresectable locally advanced or
• Histologically confirmed locally advanced or metastatic urothelial cancer.Phase Ib, subjects must have failed, be intolerant or refused the standard treatment; Phase II, subjects must not have received systemic antitumor therapy for locally advanced unresectable or metastatic urothelial carcinoma.
• An archival tumor tissue sample or a fresh tissue sample should be provided.
• Subjects must have measurable disease according to RECIST (version 1.1).